The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight ...

Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.

Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority ...

The agency is evaluating whether further regulatory action is warranted after receiving reports of neutralizing antibodies.

It’s well known that AD has a strong genetic component. Apolipoprotein E (APOE4) is expressed in 40% to 65% of all AD ...

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

Shares of Contineum Therapeutics dipped by the double-digits late Thursday after investors learned of a clinical setback for ...

The cell therapy maker said Thursday the raise will support an ongoing trial of its experimental treatment for the ...

The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a ...

Winrevair, which Merck has identified as a “growth driver,” significantly improved blood flow through the lungs to the heart ...

As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding ...

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.